Insider Selling: BioMarin Pharmaceutical Inc. (BMRN) CEO Sells 15,000 Shares of Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 15,000 shares of the business’s stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $84.73, for a total transaction of $1,270,950.00. Following the completion of the sale, the chief executive officer now directly owns 279,674 shares of the company’s stock, valued at approximately $23,696,778.02. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Jean Jacques Bienaime also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Thursday, February 15th, Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $84.63, for a total transaction of $846,300.00.
  • On Friday, January 5th, Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $90.32, for a total transaction of $903,200.00.
  • On Friday, December 29th, Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $89.61, for a total transaction of $896,100.00.
  • On Friday, December 29th, Jean Jacques Bienaime sold 20,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $89.75, for a total transaction of $1,795,000.00.

BioMarin Pharmaceutical Inc. (BMRN) traded up $0.44 during trading on Tuesday, reaching $84.26. 682,555 shares of the company’s stock were exchanged, compared to its average volume of 1,365,122. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.70 and a quick ratio of 2.12. The firm has a market cap of $14,807.68, a price-to-earnings ratio of -124.99 and a beta of 1.74. BioMarin Pharmaceutical Inc. has a 52-week low of $77.04 and a 52-week high of $100.51.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its earnings results on Thursday, February 22nd. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.06). The firm had revenue of $358.31 million for the quarter, compared to analyst estimates of $346.24 million. BioMarin Pharmaceutical had a negative net margin of 8.91% and a negative return on equity of 3.18%. research analysts anticipate that BioMarin Pharmaceutical Inc. will post -0.71 earnings per share for the current year.

Several equities research analysts have recently weighed in on BMRN shares. BidaskClub downgraded shares of BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Saturday, January 20th. JPMorgan Chase & Co. dropped their target price on shares of BioMarin Pharmaceutical from $131.00 to $129.00 and set an “outperform” rating for the company in a research report on Wednesday, January 24th. Royal Bank of Canada reissued a “hold” rating and issued a $94.00 target price on shares of BioMarin Pharmaceutical in a research report on Tuesday, February 27th. Goldman Sachs raised shares of BioMarin Pharmaceutical from a “buy” rating to a “conviction-buy” rating in a research report on Friday, December 15th. Finally, Credit Suisse Group reissued an “outperform” rating and issued a $113.00 target price on shares of BioMarin Pharmaceutical in a research report on Thursday, January 18th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $112.34.

Institutional investors have recently bought and sold shares of the business. First Manhattan Co. boosted its stake in BioMarin Pharmaceutical by 104.2% during the 4th quarter. First Manhattan Co. now owns 1,225 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 625 shares during the period. Financial Gravity Companies Inc. acquired a new position in BioMarin Pharmaceutical during the 4th quarter valued at about $112,000. Commerce Bank acquired a new position in BioMarin Pharmaceutical during the 3rd quarter valued at about $209,000. Teacher Retirement System of Texas acquired a new position in BioMarin Pharmaceutical during the 3rd quarter valued at about $220,000. Finally, First Republic Investment Management Inc. acquired a new position in BioMarin Pharmaceutical during the 3rd quarter valued at about $220,000.

COPYRIGHT VIOLATION WARNING: This news story was posted by Stock Observer and is the property of of Stock Observer. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.thestockobserver.com/2018/03/20/insider-selling-biomarin-pharmaceutical-inc-bmrn-ceo-sells-15000-shares-of-stock.html.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply